(Q56898695)

1

0 references

Anamika Bose

2

0 references

Subhasis Barik

3

0 references

Kuntal Kanti Goswami

4

0 references

Saptak Banerjee

5

0 references

Shyamal Goswami

6

0 references

Diptendu Ghosh

7

0 references

Soumyabrata Roy

8

0 references

Krishnendu Chakraborty

9

0 references

Koustav Sarkar

10

0 references

Rathindranath Baral

4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines

11

0 references

language of work or name

English

0 references

publication date

August 2011

0 references

published in

Immunotherapy

0 references

volume

3

0 references

issue

8

0 references

page(s)

949-69

0 references

cites work

1 reference

Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein

21 January 2018

1 reference

Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines

21 January 2018

1 reference

CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer

21 January 2018

1 reference

CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism

21 January 2018

1 reference

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells

21 January 2018

1 reference

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

21 January 2018

1 reference

Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer

21 January 2018

1 reference

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

21 January 2018

1 reference

Immunostimulatory neem leaf preparation acts as an adjuvant to enhance the efficacy of poorly immunogenic B16 melanoma surface antigen vaccine

21 January 2018

1 reference

Neem leaf glycoprotein helps to generate carcinoembryonic antigen specific anti-tumor immune responses utilizing macrophage-mediated antigen presentation

21 January 2018

1 reference

Neem (Azadirachta indica) leaf mediated immune activation causes prophylactic growth inhibition of murine Ehrlich carcinoma and B16 melanoma

21 January 2018

1 reference

Natural killer cell mediated cytotoxicity of tumor cells initiated by neem leaf preparation is associated with CD40-CD40L-mediated endogenous production of interleukin-12.

21 January 2018

1 reference

Neem leaf glycoprotein induces perforin-mediated tumor cell killing by T and NK cells through differential regulation of IFNgamma signaling

21 January 2018

1 reference

Neem leaf glycoprotein directs T-bet-associated type 1 immune commitment.

21 January 2018

1 reference

Neem leaf glycoprotein matures myeloid derived dendritic cells and optimizes anti-tumor T cell functions

21 January 2018

1 reference

Neem leaf glycoprotein partially rectifies suppressed dendritic cell functions and associated T cell efficacy in patients with stage IIIB cervical cancer

21 January 2018

1 reference

Neem leaf glycoprotein enhances carcinoembryonic antigen presentation of dendritic cells to T and B cells for induction of anti-tumor immunity by allowing generation of immune effector/memory response

21 January 2018

1 reference

Neem leaf preparation induces apoptosis of tumor cells by releasing cytotoxic cytokines from human peripheral blood mononuclear cells

21 January 2018

1 reference

Restoration of dysregulated CC chemokine signaling for monocyte/macrophage chemotaxis in head and neck squamous cell carcinoma patients by neem leaf glycoprotein maximizes tumor cell cytotoxicity

21 January 2018

1 reference

CD8+ T-cell responses against hemoglobin-beta prevent solid tumor growth.

21 January 2018

1 reference

Regulatory T cells, tumour immunity and immunotherapy

21 January 2018

1 reference

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

21 January 2018

1 reference

Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity

21 January 2018

1 reference

Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells

21 January 2018

1 reference

Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer

21 January 2018

1 reference

The control of CD4+CD25+Foxp3+ regulatory T cell survival

21 January 2018

1 reference

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy

21 January 2018

1 reference

OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity

21 January 2018

1 reference

Host APCs augment in vivo expansion of donor natural regulatory T cells via B7H1/B7.1 in allogeneic recipients

21 January 2018

1 reference

Regulatory T cells: key controllers of immunologic self-tolerance

21 January 2018

1 reference

Vaccination against the Forkhead Family Transcription Factor Foxp3 Enhances Tumor Immunity

21 January 2018

1 reference

A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy

21 January 2018

1 reference

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

21 January 2018

1 reference

Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells

21 January 2018

1 reference

Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma

21 January 2018

1 reference

Anti-CTL-associated antigen 4: are regulatory T cells a target?

21 January 2018

1 reference

Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells.

21 January 2018

1 reference

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference